086450 — DongKook Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩838bn
- KR₩894bn
- KR₩812bn
- 74
- 53
- 69
- 77
Annual balance sheet for DongKook Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 174,186 | 168,929 | 103,955 | 93,710 | 88,704 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 136,983 | 139,496 | 151,600 | 179,061 | 209,391 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 398,763 | 420,226 | 385,321 | 419,197 | 470,007 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 194,967 | 234,941 | 263,355 | 272,705 | 299,459 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 663,165 | 750,076 | 768,330 | 839,535 | 953,165 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 164,895 | 242,601 | 198,539 | 231,153 | 232,692 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 251,797 | 295,510 | 266,391 | 294,841 | 349,688 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 411,368 | 454,566 | 501,939 | 544,694 | 603,477 |
| Total Liabilities & Shareholders' Equity | 663,165 | 750,076 | 768,330 | 839,535 | 953,165 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |